Theraclone’s approach to therapeutic mAb discovery is unique as it enables the rapid testing of tens of thousands of fully human antibodies to find those with exceptional biological functions and activities. These antibodies can be further developed as therapeutic candidates or can form the basis for engineering including antibody drug conjugation (ADC), bispecificity, CAR-T therapy or vector delivery. The process also facilitates the discovery of novel targets that may be drugable or can be exploited for vaccine development. Successful partnerships and a strong Research and Development pipeline have repeatedly validated Theraclone’s platform technology.
I-STAR™ Proven mAb Discovery Platform
- The I-STAR™ technology starts with memory B cells taken from a blood sample of a human donor with natural resistance to the disease of interest.
- Each memory B cell has the potential to differentiate and make a unique antibody clone.
- Tens of thousands of memory B cells are grown or cultured in very small chambers called microtiter wells at a density of one cell per well.
- These cells are then activated to propagate and differentiate into antibody-producing cells.
- Antibodies that are secreted into the culture medium are harvested in sufficient quantity to enable screening for biological activity.
- Once an antibody with desired activity is found in the screen, the gene sequence for that antibody is obtained from the corresponding antibody-producing cells.
- The antibody genes can then be inserted into immortalized mammalian cells to enable production of unlimited quantities of that antibody clone for further study.
We have leveraged I-STAR technology and our antibody discovery expertise to identify potential product candidates to treat influenza, bacterial infections and various cancers.
We have also formed strategic partnerships using our I-STAR technology including:
- Worldwide exclusive license with Gilead to broadly neutralizing HIV mAbs discovered using I-STAR™
- Discovery research partnership with Pfizer to identify broadly protective monoclonal antibodies against targets in cancer and infectious disease
- Strategic alliance with Zenyaku Kogyo (ZK) to develop anti-influenza therapeutics for which ZK has commercialization rights in Japan
- Anti-HIV antibody discovery collaboration with the International AIDS Vaccine Initiative (IAVI) for which IAVI retains vaccine development rights while Theraclone holds therapeutic rights